M Vogelhuber, S Feyerabend, A Stenzl, T Suedhoff, M Schulze, J Huebner, R Oberneder, W Wieland, S Mueller, F Eichhorn, H Heinzer, K Schmidt, M Baier, A Ruebel, K Birkholz, A Bakhshandeh-Bath, R Andreesen, W Herr, A Reichle
{"title":"去势抵抗性前列腺癌患者的生物调节治疗:伊马替尼与吡格列酮、依托昔布、地塞米松和低剂量曲硫芬的II期研究","authors":"M Vogelhuber, S Feyerabend, A Stenzl, T Suedhoff, M Schulze, J Huebner, R Oberneder, W Wieland, S Mueller, F Eichhorn, H Heinzer, K Schmidt, M Baier, A Ruebel, K Birkholz, A Bakhshandeh-Bath, R Andreesen, W Herr, A Reichle","doi":"10.1007/s12307-015-0165-y","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":" ","pages":"43-4"},"PeriodicalIF":0.0000,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-015-0165-y","citationCount":"0","resultStr":"{\"title\":\"Erratum to: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan.\",\"authors\":\"M Vogelhuber, S Feyerabend, A Stenzl, T Suedhoff, M Schulze, J Huebner, R Oberneder, W Wieland, S Mueller, F Eichhorn, H Heinzer, K Schmidt, M Baier, A Ruebel, K Birkholz, A Bakhshandeh-Bath, R Andreesen, W Herr, A Reichle\",\"doi\":\"10.1007/s12307-015-0165-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9425,\"journal\":{\"name\":\"Cancer Microenvironment\",\"volume\":\" \",\"pages\":\"43-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s12307-015-0165-y\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Microenvironment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12307-015-0165-y\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Microenvironment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12307-015-0165-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Erratum to: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan.
期刊介绍:
Cancer Microenvironment is the official journal of the International Cancer Microenvironment Society (ICMS). It publishes original studies in all aspects of basic, clinical and translational research devoted to the study of cancer microenvironment. It also features reports on clinical trials.
Coverage in Cancer Microenvironment includes: regulation of gene expression in the cancer microenvironment; innate and adaptive immunity in the cancer microenvironment, inflammation and cancer; tumor-associated stroma and extracellular matrix, tumor-endothelium interactions (angiogenesis, extravasation), cancer stem cells, the metastatic niche, targeting the tumor microenvironment: preclinical and clinical trials.